Intravitreal bevacizumab (Avastin®) injection for neovascular glaucoma: A survey on 23 cases throughout 12-month follow-up

British Journal of Clinical Pharmacology

Volumn 66, Issue 5, 2008, Pages 667-673

  Costagliola, Ciro ^a   Cipollone, Ugo ^b   Rinaldi, Michele ^c   Della Corte, Michele ^c   Semeraro, Francesco ^d   Romano, Mario R ^a,e  

^a UNIVERSITY OF MOLISE   (Italy)

^b Ospedale G Vietri   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e Dipartimento DiMedicina e Scienze della Salute   (Italy)

Author keywords

Angle neovascularization; Bevacizumab (Avastin ); Iris neovascularization; Neovascular glaucoma; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; DORZOLAMIDE; PROSTAGLANDIN; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EDEMA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS NEOVASCULARIZATION; MALE; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 55149095947     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03278.x     Document Type: Article

References (30)

1. Pagenstecher H. Beitrage zur Lehre vom hamorrhagischen Glaukom. Graefes Arch Ophthalmol 1871 17 : 98 130.
2. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res 2007 26 : 470 85.
3. Manschot WA. Retinal neovascularization after retinal vaso-obliteration. Frequency-origin-morphology. Doc Ophthalmol 1983 55 : 117 20.
4. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998 105 : 232 7.
5. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005 40 : 352 68.
6. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005 46 : 726 33.
7. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006 26 : 354 6.
8. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006 37 : 144 6.
9. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006 142 : 158 60.
10. Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott IU. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 2006 84 : 556 7.
11. Mason JO III., Albert MA Jr., Mays A, Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006 26 : 839 41.
12. Geitzenauer W, Michels S, Prager F, Kornek G, Vormittag L, Rosenfeld P, Schmidt-Erfurth U. Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 2006 223 : 822 7.
13. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006 142 : 1054 6.
14. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res 2007 39 : 121 2.
15. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007 41 : 614 25.
16. Vatavuk Z, Bencic G, Mandic Z. Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion. Eur J Ophthalmol 2007 17 : 269 71.
17. Batioǧlu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol 2008 28 : 59 61.
18. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 2007 35 : 494 6.
19. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007 16 : 437 9.
20. Kelkar AS, Kelkar SB, Kelkar JA, Nagpal M, Patil SP. The use of intravitreal bevacizumab in neovascular glaucoma: a case report. Bull Soc Belge Ophtalmol 2007 303 : 43 5.
21. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007 23 : 487 91.
22. Ichhpujani P, Ramasubramanian A, Kaushik S, Pandav SS. Bevacizumab in glaucoma: a review. Can J Ophthalmol 2007 42 : 812 5.
23. Ehrenberg M, McCuen BW II., Schindler RH, Machemer R. Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids. Ophthalmology 1984 91 : 321 5.
24. Laatikainen L. A prospective follow-up study of panretinal photocoagulation in preventing neovascular glaucoma following ischaemic central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 1983 220 : 236 9.
25. Tanaka T, Matsuo T, Ohtsuki H. Aqueous vascular endothelial growth factor increases in anterior segment ischemia in rabbits. Jpn J Ophthalmol 1998 42 : 85 9.
26. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM et al. Comparisons of the intraocular tissue distribution pharmacokinetics and safety of 125 I-labeled Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999 27 : 536 44.
27. Ferrara N. Vascular endothelial growth factor: basic science in clinical progress. Endocrinol Rev 2004 25 : 581 611.
28. Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007 245 : 1837 42.
29. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007 24 : 643 62.
30. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007 91 : 1244 6.